Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the best stocks under $5 with huge upside potential. Chardan reiterated a Buy rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) on April 10, setting a $16 price target on the stock. The rating update came after Replimune received a second complete response letter from the FDA for RP1 in combination with nivolumab in adults with unresectable advanced cutaneous melanoma who had progressed after anti-PD-1 therapy. The firm told investors in a research note that it sees the CRL as a positive factor for the company’s Amtagvi’s near-term competitive position in post-checkpoint melanoma. However, it also added that more direct competition from cell therapies “could be on the horizon” in 2027.
For additional reference, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported a 30% quarterly revenue growth in its fiscal Q4 and full year 2025 results, driven by Amtagvi demand. Management also reported that gross margin rose to 50%, while fiscal year 2025 revenue of $264 million attained annual guidance.
Iovance Biotherapeutics (NASDAQ:IOVA) is a biopharmaceutical company that develops and commercializes cell therapies as novel cancer immunotherapy products. The company’s lead product candidate is LN-144, which is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for metastatic melanoma.
While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.